CNS Market Momentum CNS-focused therapies and the performance of CAPLYTA indicate a favorable demand environment in neurology and psychiatry, presenting opportunities to partner on access programs, specialty distribution, and patient adherence initiatives to accelerate uptake.

Commercial Scale Expansion Evidence of a growing commercial footprint with an expanded sales force signals a need for field enablement, training, CRM optimization, and payer access support to improve launch efficiency and channel reach.

Strategic Partnerships Industry M&A activity around CNS assets suggests openness to licensing, co-development, and manufacturing collaborations to scale therapies, accelerate development timelines, and expand geographies.

Digital and Data A modern tech stack points to ripe opportunities for digital health collaborations, marketing automation, data analytics, real-world evidence programs, and secure cloud infrastructure to enhance commercialization and regulatory compliance.

Funding Readiness Public financing and liquidity position enable faster market entry and pipeline progression, with potential to support market access strategy, pricing and reimbursement planning, and international expansion initiatives.